YH001
2020.05.26
Drug : YH001(CTLA-4)
Progress : Phase I clinical trial
Indication : Solid tumor
Country/Region : Australia
Study Title : A First-in-human (FIH), Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of YH001 in Combination with Toripalimab Injection in Subjects with Advanced Solid TumorsLink to Trial : https://clinicaltrials.gov/ct2/show/NCT04357756
Country/Region:China
Study Title : A Phase I/II, Dose Escalation and Dose Expansion Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Recombinant Anti-CTLA-4 Humanized Monoclonal Antibody Injection (YH001) in Subjects with Advanced Solid Tumors
Link to Trial : http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml
More information
Eucure (Beijing) Biopharma Co., Ltd.
23F, Tower 3, China Central Place, No.77, Jian Guo Road, Chaoyang District, Beijing, P. R. China,100025
WeChat
2020 Eucure & Biocytogen京ICP备18006768号-1